Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma

[1]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[2]  R. Figlin,et al.  Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. , 1995, Urology.

[3]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Logothetis,et al.  Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma , 1994 .

[5]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[6]  M. Zelefsky,et al.  Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Kerbl,et al.  Spontaneous regression of osseous metastasis in renal cell carcinoma. , 1993, The Australian and New Zealand journal of surgery.

[8]  Wirth Mp.  Immunotherapy for metastatic renal cell carcinoma. , 1993 .

[9]  N. Vogelzang,et al.  Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. , 1992, The Journal of urology.

[10]  M. Atkins,et al.  A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Bander,et al.  Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. , 1990, Cancer research.

[12]  P. Goodman,et al.  Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. , 1990, Journal of the National Cancer Institute.

[13]  A. Yagoda.  Chemotherapy of renal cell carcinoma: 1983-1989. , 1989, Seminars in urology.

[14]  E. Borden,et al.  Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma. , 1989, Journal of interferon research.

[15]  R. Oliver,et al.  Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. , 1989, British journal of urology.

[16]  S. D. Davis,et al.  Spontaneous regression of pulmonary metastases from renal cell carcinoma. , 1989, Urology.

[17]  E. Werner,et al.  Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. , 1989, Advances in clinical chemistry.

[18]  S. Fosså,et al.  Spontaneous regression of cerebral and pulmonary metastases in renal cell carcinoma. , 1989, Scandinavian journal of urology and nephrology.

[19]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.

[20]  S. Conrad,et al.  Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial. , 1988, Arzneimittel-Forschung.

[21]  R. Figlin,et al.  Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Longo,et al.  The determination of an immunologically active dose of interferon-gamma in patients with melanoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Oliver,et al.  A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. , 1988, Molecular biotherapy.

[24]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[25]  R. Kurzrock,et al.  Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. , 1987, Journal of biological response modifiers.

[26]  J. Rinehart,et al.  Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. , 1986, Journal of biological response modifiers.

[27]  J. Quesada,et al.  Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Harris.  Hormonal therapy and chemotherapy of renal-cell carcinoma. , 1983, Seminars in oncology.

[29]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .